Starch Granule Swelling Drives Tablet Disintegration Once Compression Force Falls Below a Defined Upper Limit

Unmodified maize starch of pharmacopoeial grade functions as a swelling-type disintegrant in immediate-release tablet matrices. The native granules possess a median particle size near 15 µm with a distribution spanning 2–32 µm and an amylose content of 25–28% for normal dent maize. Water penetrates the tablet pore network, diffuses into the amorphous regions of the starch granule, and disrupts hydrogen bonding within the amylopectin crystalline lamellae. The resulting volumetric expansion generates radial tensile stress that fractures the compact once the internal stress exceeds the tablet tensile strength. Swelling capacity is not an absolute material constant but is influenced by temperature, pH, and prior mechanical history. At 37°C in purified water, native maize starch granules may increase in diameter by approximately 30–50% before complete gelatinization; reported swelling power values fall in the 10–30 g/g range at 95°C. This swelling behaviour is pH-independent and remains operative across the gastric pH range of 1.2–7.5, which distinguishes maize starch from acid-dependent effervescent disintegrants.

Formulation practice restricts native maize starch to 5–15% w/w as an intra-granular or extra-granular disintegrant. Below 5% w/w the internal stress generated upon wetting is insufficient to overcome tablet tensile strength, particularly for compacts above 1.0 MPa hardness. Above 15% w/w two competing effects appear: the starch begins to act as a diluent, and starch-rich domains may form a superficial gel layer that slows water ingress and delays disintegrant activation. The critical process window resides in compression force. At low compaction loads below 10 kN on a single-punch press, tablet porosity remains above 10–15% and water wicks rapidly. As main compression force increases toward 15–20 kN, starch granules undergo plastic deformation and porosity drops below 5%, reducing disintegrant action. Production-scale instrumented rotary presses with precompression rollers typically operate between 8 kN and 18 kN for starch-containing immediate-release formulations. Above 20 kN, capping and lamination may also appear because of elastic recovery of native starch granules after decompression. Tablet friability should be verified according to USP <1216> because starch-rich compacts can exceed 1.0% friability when compression force is reduced to preserve disintegration speed.

Disintegration testing follows USP <701>, Ph. Eur. 2.9.1, or JP 6.09 using purified water held at 37±2°C with disc immersion. Immediate-release uncoated tablets containing maize starch as the sole disintegrant commonly disintegrate within 5–15 min, although the final target is monograph-specific. Lubricant selection modulates this performance. Magnesium stearate at 0.5–1.0% w/w blended for more than 5 min with a starch-containing granulation can deposit hydrophobic films on starch particles and extend disintegration time by 2–4 min in worst-case conditions. Stearic acid and sodium stearyl fumarate produce less retardation but are not universally compatible with all active pharmaceutical ingredients. Extra-granular addition of native maize starch gives faster disintegration but lower tablet hardness, while intra-granular addition preserves granule strength and prolongs disintegrant action. To balance both attributes, formulators frequently split the starch fraction between the granulation and the external phase at a 1:1 ratio.

Loss on drying for native maize starch is limited to NMT 14.0% under the USP-NF and Ph. Eur. monographs, but tablet formulations stored above 60% RH may absorb sufficient moisture to soften the compact and alter the swelling response. At 25°C/75% RH, equilibrium moisture sorption of unmodified maize starch falls in the 12–18% range, which is reversible but can affect in-process blending and flow. Pre-conditioning the starch at 40–50°C for 2–4 h before direct compression is standard when ambient relative humidity exceeds 60%. Because the swelling mechanism is independent of ionic strength and pH, maize starch remains functional in unbuffered and buffered dissolution media without an activation threshold, unlike superdisintegrants that rely on rapid wicking through a rigid particle skeleton.

How Does Gelatinized Maize Starch Paste Control Granule Density and Compression Profile?

When maize starch is dispersed in purified water and heated, the granules pass through a gelatinization transition with an onset near 62°C, a peak near 67–72°C, and completion near 80°C at neutral pH. Differential scanning calorimetry at a heating rate of 10°C/min records a gelatinization enthalpy of approximately 12–15 J/g for normal maize starch. In wet granulation, the binder is prepared as a starch paste at 5–15% w/w. The paste exhibits pseudoplastic flow; apparent viscosity falls as impeller shear increases, which permits uniform distribution in a high-shear granulator while retaining sufficient cohesive strength to bind primary particles. Paste preparation is carried out in a jacketed kettle at 80–90°C with continuous agitation until the slurry becomes translucent. Overheating beyond 95°C or prolonged holding above 85°C reduces paste viscosity through amylose depolymerization and produces weak granules. On cooling, maize starch paste retrogrades and develops a gel network; the prepared paste is therefore held at 50–60°C before addition to avoid viscosity drift and nozzle fouling on production equipment.

In vertical high-shear granulators with impeller tip speeds of 5–10 m/s and chopper speeds of 1500–3000 rpm, the starch paste is added to the dry blend over 2–5 min. Torque or power consumption curves are used to detect the granulation endpoint; a sharp torque increase indicates the transition from pendular to funicular liquid saturation. The target endpoint is conventionally set at 70–85% of the maximum torque plateau to avoid over-densification. Granules produced with 5–10% w/w maize starch paste show improved flow index relative to raw starch, with Carr index values falling from 30–40 for the ungranulated powder to 15–20 for the milled granulation. Drying in a fluid-bed dryer at 50–60°C inlet air temperature is preferred over static tray drying because it preserves granule porosity and disintegration performance. Final moisture of the dried granulation should be maintained at 2–4% w/w for tableting; lower moisture increases friability and punch-film picking, while higher moisture promotes picking and can increase residual moisture in finished tablets beyond the monograph limit.

Tablets prepared from starch-paste granulations can tolerate higher main compression forces than direct-compression starch blends because the gelatinized binder reduces elastic recovery. Target hardness values between 40 N and 80 N are commonly achieved at compression forces of 10–18 kN on rotary presses, with friability below 0.8% according to USP <1216>. However, gelatinized starch paste retards disintegration if used above 10% w/w, because the dried gel network must rehydrate before tablet fracture. For this reason, a portion of native maize starch is frequently added extra-granularly as a disintegrant to offset the binding effect. The total starch content should be tracked because the compendial monograph does not distinguish between native and gelatinized fractions; both contribute to the final loss on drying and ash limits of the finished tablet.

In hard gelatin capsule filling, native maize starch is used as a bulking diluent to adjust the fill weight of a metered dose without altering the dissolution profile of freely soluble actives. Flow, not compressibility, is the controlling constraint. Maize starch powder exhibits a Carr index in the 30–40 range, a Hausner ratio of 1.4–1.6, and an angle of repose between 40° and 50° when measured according to USP <1174>. Such flow properties are marginal for dosator-type capsule fillers and generally inadequate for tamping-pin machines running above 30,000 capsules/h without forced feeding. Production-scale dosator machines require a free-flowing blend with a minimum bulk density of 0.5–0.7 g/cm³ to maintain fill weight RSD below 2.0% per USP <905>. Blending maize starch with 0.5–1.0% w/w colloidal silicon dioxide or 0.5% w/w magnesium stearate reduces interparticle friction, but the lubricant can retard drug release for poorly water-soluble actives. In such cases, increasing the maize starch fraction while reducing lubricant contact time to less than 3 min is a documented process compromise on large-scale tumble blenders.

Capsule shell stability is coupled to the moisture content of the maize starch component. The USP-NF corn starch monograph permits NMT 14.0% loss on drying, but capsule fills above 10% moisture content at the time of encapsulation can cause localized shell softening and deformation during storage. Pre-drying at 40–50°C for 2–4 h in a convection oven or under vacuum is required when the material has been stored above 60% RH. Native maize starch has a water activity below 0.5 after drying, which is compatible with hard gelatin and HPMC capsule shells. For hygroscopic actives, maize starch is preferred over sorbitol or lactitol because it does not lower the glass transition temperature of the amorphous drug phase. However, native maize starch provides no dissolution enhancement and offers no plasticizing function for the capsule shell; its role is limited to fill weight adjustment and moisture moderation. In formulations containing deliquescent actives, additional desiccant packaging is required because maize starch cannot irreversibly scavenge moisture.

When Liquid Glucose Syrup from Maize Starch Feeds Injectable Dextrose Crystallization

Injectable-grade dextrose monohydrate is not produced by direct use of native maize starch in a parenteral formulation; the starch must first be hydrolyzed to a high-dextrose-equivalent syrup, purified, and crystallized. Normal maize starch selected for this pathway must satisfy the USP-NF Corn Starch monograph, including protein content NMT 1.0%, sulfated ash NMT 0.6%, heavy metals NMT 20 ppm, and microbial counts below compendial acceptance criteria. Because the starch is used as a starting material for injectable manufacture, it is controlled under the same Good Manufacturing Practice framework as an active pharmaceutical ingredient, with additional bioburden and bacterial endotoxin in-process controls beyond the oral excipient monograph. Acid hydrolysis is carried out with 0.5–1 M hydrochloric acid at 140–150°C for 5–10 min, producing a syrup of DE 90–95; enzymatic hydrolysis with a thermostable α-amylase at 105–110°C for 1–3 h followed by glucoamylase at 55–60°C for 24–72 h reaches DE 97–98.5 with fewer 5-hydroxymethylfurfural by-products. The enzymatic route is standard for pharmaceutical dextrose because it reduces colour bodies and minimises the load on subsequent activated-carbon treatment.

The raw syrup is clarified with 0.2–0.5% w/w activated carbon at 70–80°C for 30–60 min, subjected to cation-anion exchange polishing to remove ash ions and colour precursors, concentrated to 70–75% dry substance, and cooled under controlled conditions. Crystallization of dextrose monohydrate is conducted in cooling crystallizers at 40–50°C; the crystals are washed with chilled purified water and dried to a final moisture consistent with the USP Dextrose Monohydrate monograph. For parenteral use, purified dextrose is reconstituted to 5% w/v or 10% w/v, adjusted to pH 3.5–6.5 with hydrochloric acid or sodium hydroxide, and sterilized at 121°C for 15 min in a steam autoclave. Bacterial endotoxin release testing is performed on the finished solution with a specification commonly set at NMT 0.5 EU/mL for large-volume parenterals. Native maize starch itself is not injectable and cannot be introduced into a parenteral container without prior hydrolysis, fractionation, and depyrogenation; any attempt to do so would violate compendial particulate-matter limits under USP <788> and create an unacceptable embolic risk.

A second injectable pathway uses maize starch as the polymeric backbone for hydroxyethyl starch, a plasma volume expander. This application preferentially uses waxy maize starch with amylopectin content above 99%, not normal dent maize starch with 25–28% amylose, because the lower amylose fraction facilitates uniform hydroxyethyl substitution and a consistent molar mass distribution. Hydroxyethyl starch 130/0.4 is produced by alkaline hydroxyethylation followed by acid hydrolysis to a weight-average molecular weight of 130,000–150,000 Da and a molar substitution of 0.38–0.45. Normal maize starch may be used for non-parenteral starch derivatives, but its amylose-rich fractions can produce turbid solutions and broader molecular weight dispersity in the final hydroxyethyl starch product. Published data for injectable formulations derived from normal maize starch remain limited; compendial feedstock certification does not by itself establish suitability for parenteral synthesis without additional endotoxin, bioburden, and molecular-weight distribution controls.

Dry syrup and reconstitutable oral powder formulations incorporate native maize starch as a moisture-moderating diluent at 10–30% w/w to prevent caking of hygroscopic actives inside aluminium foil or aluminium-laminate sachets. The starch absorbs ambient humidity slowly; its equilibrium moisture at 25°C/75% RH is approximately 13–18%, lower than that of spray-dried lactose under the same conditions. This property reduces local water activity in the powder blend and protects moisture-labile actives such as β-lactam antibiotics before reconstitution. Flow improvement is secondary but measurable: addition of 10% w/w maize starch to a cohesive API can lower the angle of repose by 5–10° and improve sachet fill weight variability on auger-type powder fillers operating at 60–120 doses/min. The mean fill weight and RSD should be verified in accordance with USP <905> because the flow improvement from maize starch is not sufficient to correct severe feed-frame segregation in high-speed sachet lines.

After reconstitution with purified water, native maize starch does not swell at room temperature and settles rapidly; it is not a suspending agent. Sedimentation volume of a reconstituted dry suspension containing only maize starch and drug may fall below 0.2 within 10 min, which is unacceptable for oral dosing. Polysaccharide suspending agents such as xanthan gum, sodium carboxymethylcellulose, or pregelatinized starch are therefore added at 0.3–1.0% w/v to impart yield stress. Maize starch contributes to redispersibility by preventing hard packing at the bottom of the bottle, but final shake-to-dose uniformity should be verified against the reconstitution time specified in the product monograph. Oral powders must comply with microbial examination per USP <61> and <62>, with the starch component tested before blending because it is a natural product and may carry bioburden from agricultural processing. For sugar-free paediatric formulations, maize starch as a diluent reduces the osmotic load compared with sucrose but does not provide sweetness; a compatible non-nutritive sweetener is required.

Extrusion-Spheronization Aid for Multiparticulate Dosage Forms

Extrusion-spheronization of drug-loaded pellets uses maize starch as a filler and spheronization aid in combination with microcrystalline cellulose (MCC), which supplies the required plasticity and water-retention capacity. A typical pellet formulation consists of 20–30% w/w active pharmaceutical ingredient, 40–60% w/w MCC, 10–20% w/w maize starch, and water or binder solution added to a granulation moisture of 15–20% w/w. The starch reduces surface tackiness of the wet mass and improves the cutting behaviour of the extrudate through radial or twin-screw extruders with die diameters of 0.8–1.2 mm and screw speeds of 30–100 rpm. During spheronization on a cross-hatched plate at 500–1000 rpm for 3–10 min, maize starch modifies the plastic-to-brittle transition of the MCC matrix and contributes to the rounding of cylindrical extrudate fragments into spherical pellets with an aspect ratio below 1.2. This role is not interchangeable with that of MCC; native starch does not provide the high water-retention capacity or the plastic deformation required to sustain spheronization without MCC.

The functional window for native maize starch in pellet formulations is narrow. At starch loadings above 20% w/w, the extrudate becomes brittle and spheronization generates fines above 20% w/w, reducing the yield of the 0.8–1.25 mm fraction. At starch loadings below 5% w/w, effects on surface smoothing are negligible and processing behaviour is governed entirely by MCC. Moisture control during granulation is the primary process risk: if wet-mass moisture exceeds 20% w/w, densification and spheronizer plate sticking occur; below 14% w/w, the extrudate may overheat and produce rough-surfaced pellets that fail film-coating uniformity checks. Drying of pellets is carried out in a fluid-bed dryer at 40–50°C inlet air temperature to avoid retrogradation of amylose leached from the starch granule surface, which can form a hard film and retard drug release from coated multiparticulates. Pellet size distribution and friability are verified before coating using sieve analysis and a tumbling friability tester.

Maize starch also functions as a pore former in enteric-coated pellets. When pellets containing 10–20% w/w native maize starch are coated with methacrylic acid copolymer films, starch granules at the pellet surface hydrate after gastric emptying and create channels that facilitate drug release at intestinal pH. The channel formation is pH-sensitive only through the coating polymer, not through the starch itself. This mechanism has been characterized by scanning electron microscopy of leached pellet cross-sections and by drug-release testing according to USP <711> apparatus 2 at 50–100 rpm. Process validation for starch-containing pellet formulations requires verification of pellet size distribution, sphericity, friability as defined by the finished dosage monograph, and dissolution release profiles over the intended pH range of 1.2–6.8. Batches failing the sphericity threshold below 0.8 on the aspect ratio typically show inconsistent film thickness and variable lag time in enteric release, a failure mode observed on production-scale spheronizers when plate load exceeds the design capacity of the equipment.